×
Apollomics EBIT Margin 2021-2024 | APLM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Apollomics ebit margin from 2021 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
Apollomics EBIT Margin 2021-2024 | APLM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Apollomics ebit margin from 2021 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$245.4B
Amgen (AMGN)
$157.5B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100B
Bristol Myers Squibb (BMY)
$98.1B
CSL (CSLLY)
$85.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$59.9B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26.9B
Royalty Pharma (RPRX)
$20.9B
Biogen (BIIB)
$19.9B
Incyte (INCY)
$16.6B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
Moderna (MRNA)
$10.9B
QIAGEN (QGEN)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.1B
Roivant Sciences (ROIV)
$8B